Oligonucleotide Therapeutics and Delivery Conference 2021

Programme du congrès

Lieu : London

Pays : Royaume-Uni

Langue : ENG

Date de début :

Date de fin :

https://go.evvnt.com/774501-0?pid=4319

Spécialités : Génétique Médicale

Oligonucleotide therapeutics - the emerging medicine class - are harnessing the therapeutic benefit of targeting genetic material via antisense, mRNA, RNAi, saRNA and siRNA. Their market growth: CAGR of 13.7% projected to reach USD 8.2 billion by 2024 is driven by their potential to provide more efficacious and less toxic alternatives to small molecules. They bring about the ability to affect targets that have been considered "non-draggable". Heavy investments in oligonucleotide therapeutic discovery have created an emerging market need for drug delivery technologies.